文献速递白血病造血干细胞移植与细胞治疗

以维奈克拉为基础的挽救治疗作为移植桥接在复发/难治性急性髓系白血病患者中可行且有效

Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.
PubMed 文献 · Blood Adv · 2025-01-01

本研究比较37例接受以维奈克拉(VEN)为基础挽救治疗桥接异基因造血干细胞移植(allo-HCT)的复发/难治性急性髓系白血病(AML)患者与90例来自德国研究联盟白血病AML登记组接受非VEN挽救治疗的患者。VEN组总缓解率高于对照组(62% vs 42%;P = .049),中位无事件生存期显著延长(8.0个月 vs 3.7个月;P = .006)。倾向性评分匹配显示VEN组总生存有改善趋势(HR 0.70;95%CI 0.41-1.22;P = .20)。

要点

  • VEN组总缓解率62% vs 对照组42%(P = .049)。
  • VEN组中位无事件生存期8.0个月 vs 对照组3.7个月(P = .006)。
  • 倾向性评分匹配后VEN组总生存有改善趋势(HR 0.70;95%CI 0.41-1.22;P = .20)。

核心结论

  • 以维奈克拉为基础的挽救治疗是复发/难治性AML患者桥接allo-HCT安全且有效的策略。

研究设计与样本

  • 采用倾向性评分匹配(PSM)比较37例接受以VEN为基础挽救治疗桥接allo-HCT的复发/难治性AML患者与90例来自德国研究联盟白血病AML登记组接受非VEN挽救治疗(由主治医师选择,TPC)的患者。

主要发现

  • VEN组总缓解率高于TPC对照组(62% vs 42%;P = .049)。
  • VEN组73% vs TPC组63%的患者桥接至allo-HCT(P = .41)。
  • VEN组中位随访34.3个月,TPC组21.0个月;中位总生存分别为15.8个月(95%CI 10.6至不可评估)和10.5个月(95%CI 6.8-19.6;P = .15)。
  • 倾向性评分匹配显示VEN组总生存有改善趋势(HR 0.70;95%CI 0.41-1.22;P = .20)。
  • VEN组中位无事件生存期显著长于TPC组(8.0个月 vs 3.7个月;P = .006)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/refractory (R/R) AML; however, comparative studies with conventional therapies for fit patients as a bridge-to-transplant strategy are limited. Using propensity score matching (PSM), we compared 37 patients with R/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non-VEN-containing salvage therapy according to their treating physician's choice (TPC). The overall response rate among VEN patients was higher than the TPC control cohort (62% vs 42%; P = .049). Overall, 73% of VEN-treated patients vs 63% of TPC patients were bridged to allo-HCT (P = .41). After a median follow-up of 34.3 months for the VEN and 21.0 months for the TPC cohort, the median overall survival (OS) were 15.8 months (95% confidence interval [CI], 10.6 to not evaluable) and 10.5 months (95% CI, 6.8-19.6; P = .15), respectively. PSM revealed a trend toward improved OS for VEN patients (hazard ratio, 0.70; 95% CI, 0.41-1.22; P = .20). Median event-free survival was significantly longer in the VEN cohort (8.0 months) than the TPC cohort (3.7 months; P = .006). Our data suggest that VEN-based salvage therapy is a safe and effective bridge to allo-HCT for this difficult-to-treat AML patient population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Unglaub JM, Schlenk RF, Middeke JM, et al. Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML. Blood Adv. 2025. PMID: 39293081. doi:10.1182/bloodadvances.2024013086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。